Endo International plc

Q4 2018
Earnings Report

February 28, 2019

endo

Forward Looking Statements; Non-GAAP Financial Measures

This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future projects” or similar expressions are forward looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward looking statements involve risks and uncertainties. Although Endo believes that these forward looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the United States and Canada including under the caption “Risk Factors” in Endo’s Form 10-K, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval (“SEDAR”) and as otherwise enumerated herein or therein, could affect Endo’s future financial results and could cause Endo’s actual results to differ materially from those expressed in any forward looking statements. The forward looking statements in this presentation are qualified by these risk factors. Endo assumes no obligation to publicly update any forward looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.

This presentation may refer to non-GAAP financial measures, including, among others, adjusted diluted EPS, adjusted EBITDA, adjusted income from continuing operations, adjusted gross margin, adjusted operating expenses, adjusted effective tax rate, adjusted revenue and adjusted weighted average diluted shares that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Endo utilizes these financial measures because (i) they are used by Endo, along with financial measures in accordance with GAAP, to evaluate the Endo's operating performance; (ii) Endo believes that they will be used by certain investors to measure Endo's operating results; (iii) the Compensation Committee of Endo's Board of Directors uses adjusted diluted EPS and Adjusted EBITDA, or measures derived from such, in assessing the performance and compensation of substantially all of Endo's employees, including executive officers and (iv) Endo's leverage ratio, as defined by Endo's credit agreement, is calculated based on non-GAAP financial measures. Endo believes that presenting these non-GAAP measures provides useful information about Endo's performance across reporting periods on a consistent basis by excluding certain items, which may be favorable or unfavorable, pursuant to certain specified procedures. These non-GAAP measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP. Endo's definition of these non-GAAP measures may differ from similarly titled measures used by others. Investors are encouraged to review Endo’s current report on Form 8-K furnished to the SEC on February 28, 2019, including exhibit 99.1 thereto, for Endo's definition of the non-GAAP financial measures in this presentation as well as a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures.

Today's Agenda

- Overview
- Q4 2018 Segment Results
- Milestones and Pipeline
- 2019 Financial Guidance
- Q&A

Evolving our Strategic Priorities
Recognizing our progress and defining next phase

1
Reshape our Organization for Success

- **Simplify** our business through process and technology enhancements
- **Drive** productivity improvements
- **Leverage** the new Endo Culture to develop, retain and attract top talent

2
Build Our Portfolio and Capabilities for the Future

- **Expand** the breadth of our Sterile Injectables portfolio
- **Invest** in the continued growth of our highly focused Specialty portfolio
- **Strengthen** our Generics business portfolio and profile for the future
- **Execute** to flawlessly bring the first injectable treatment for cellulite to market

3
Drive Margin Expansion and De-Lever

- **Drive** EBITDA margin improvements through operational execution and continuous improvements
- **De-lever** 3-4x range over time; committed to a highly disciplined capital allocation approach
- **Accelerate** return to EBITDA dollar growth through smart business development

endo

Overview

- Q4’18 total enterprise revenue y-o-y growth of ~2% driven by continued strong performance in core growth areas
  - U.S. Branded Sterile Injectables (+32% in Q4’18) and U.S. Branded Specialty portfolio (+15% in Q4’18)
- Delivered Q4’18 adjusted EBITDA of $344 million reflecting ~5% y-o-y growth
- Continued progress with building our portfolio for the future
  - Positive CCH for cellulite trials top-line results, expect BLA filing in 2H19, commercial launch in 2H20
- Providing full-year 2019 guidance on revenue, adjusted diluted EPS and adjusted EBITDA from continuing operations

endo

Q4 2018 Snapshot

Revenue (US $M)	Q4 2018	Q4 2017
U.S. Branded – Specialty and Established Pharmaceuticals	$230	$228
U.S. Branded – Sterile Injectables	$259	$196
U.S. Generic Pharmaceuticals	$264	$303
International Pharmaceuticals	$34	$41
Total	**$786**	**$769**

Adjusted EBITDA	**$344**	**$327**

Table may not total due to rounding

Q4 2018 Performance: U.S. Branded – Specialty & Established Pharmaceuticals

Reported Revenues in $ Millions



Specialty Products

- 15% Y-o-Y growth in Specialty Products
- 30% Xiaflex Y-o-Y growth
- 12% Nascobal Y-o-Y growth
- 36% Aveed Y-o-Y growth
- Expect FY'19 U.S. Specialty Products revenue growth of low double digit percentage range
- Expect FY'19 XIAFLEX® growth in the mid to high teens percentage range

Pipeline

- Reported positive results from two Phase 3 CCH clinical trials for the treatment of cellulite in the buttocks
- Expect BLA filing in 2H19, commercial launch in 2H20

Q4 2018 Performance: U.S. Branded – Sterile Injectables

Reported Revenues in $ Millions



Sterile Products

- 32% Y-o-Y growth driven by ADRENALIN® (+60%) and VASOSTRICT® (+22%)
- Expect FY'19 Sterile Injectables revenue to grow in the high single to low double digit percentage range
- Expect FY'19 VASOSTRICT® revenue to grow by low double digit percentage

endo

Q4 2018 Performance: U.S. Generic Pharmaceuticals

Reported Revenues in $ Millions



U.S. Generics

- Performance reflects competitive pressure
- Focused on technically challenging, high barrier generic products across multiple therapeutic areas
- Expect 2019 to be transitional year as late 2018 competitive events annualize and key Par product launches are expected in late 2019 and beyond
- FY’19 U.S. Generic Pharmaceuticals revenue expected to decline by mid to high teens percentage range

Q4 2018 Performance: International Pharmaceuticals

Reported Revenues in $ Millions



* Includes sales from Endo Ventures Limited and Par UK

International

- Q4'18 performance impacted by October 2017 divestiture of Somar
- Expect FY'19 International Pharmaceuticals revenues to decline by ~20%

Milestones and Pipeline

- Positive results from the Phase 3 CCH for cellulite clinical trials; additional CCH studies in development (focused on dosing and injection techniques in the thighs and buttocks, non-obese subjects with less severe cellulite)
- 3rd party relationships, such as Nevakar, expands capabilities
- Continue to pursue promising external opportunities
- Expect ~15 Sterile and Generic launches in 2019

Pipeline & Select FTF/FTM Settlements Estimated Launches late '19 and beyond

~85 ANDAs Filed w/FDA

~1/2 ANDA's FTF/FTM

~70 Projects in Development

Opportunistic Business Development partnerships

Product	FY'18 IQVIA/Brand Sales	Settlement
DEXILANT® (dexlansoprazole)	~$1,200m	Confidential terms
AFINITOR® (everolimus)	~$800m	Confidential terms
AMITIZA® (lubiprostone)	~$500m	Q1 2021
CIPRODEX® (ciprofloxacin; dexamethasone otic suspension)	~$470m	2020
KUVAN® (sapropterin)	~$433m	Q4 2020
GATTEX® (teduglutide)	~$350m	Confidential terms

- IQVIA sales for 12 months
- GATTEX® LTM brand sales as of 6/30/18

endo

Q4 2018: Financial Results (Continuing Operations*)

(US $M, except EPS)	US GAAP		Non-GAAP	
	Q4 ’18	Q4 ’17	Q4 ’18	Q4 ’17
Revenue	$786	$769	$786	$769
Gross Margin	44.9%	34.2%	64.2%	65.7%
Operating (Loss) Income	($150)	($304)	$317	$299
Net (Loss) Income	($265)	($272)	$175	$174
Effective Tax Rate	0.7%	36.0%	3.2%	(2.1%)
Diluted (Loss) Income per share	($1.18)	($1.22)	$0.75	$0.77
Weighted Average Diluted Shares Outstanding	224	223	233	225

* Continuing Operations excludes ASTORA (formerly known as AMS Women’s Health)

endo

2019 Financial Guidance (Continuing Operations*)

Measure	FY 2019
Revenue	$2.76B – $2.96B
Adjusted EBITDA	$1.24B – $1.34B
Adjusted Diluted EPS	$2.00 – $2.25

The Company's 2019 Financial Guidance is Based on the Following Assumptions:

- Adjusted gross margin of approximately 65.0% to 66.0%
- Adjusted operating expenses as a percentage of revenue to be approximately 24.5% to 25.0%
- Adjusted interest expense of approximately $550 to $560 million
- Adjusted effective tax rate of approximately 17.5% to 18.5%
- Full-year adjusted diluted shares outstanding of approximately 234 million
- Revenue, Adjusted EBITDA, and Adjusted Diluted EPS weighted more towards the 2nd half of 2019

* Continuing Operations excludes ASTORA (formerly known as AMS Women's Health)

2019 Segment Guidance

Segment	YOY % Change in Revenues	Adjusted Gross Margin %
U.S. Branded – Specialty & Established Pharmaceuticals	Flat to Low single digit growth	Low 80's
U.S. Branded – Sterile Injectables	High single to low double digit growth	High 70's
U.S. Generic Pharmaceuticals	Mid to High teens decline	Low to mid 30's
International Pharmaceuticals	~ 20% decline	Low 50's

The Company's 2019 Segment Guidance is Based on the Following Assumptions:

- Branded Specialty Product Portfolio* revenue expected to grow low double digit percentage
- Xiaflex revenue expected to grow in the mid to high teens percentage
- Vasostrict revenue expected to grow low double digit percentage

*Beginning in 2019, TESTOPEL® will be reclassified from Specialty Products to Established Products within the U.S. Branded – Specialty & Established Pharmaceuticals segment

endo

Cash Flow Prior to Debt Payments

US $M	2018 Actual	FY 2019 Guidance Low	FY 2019 Guidance High
Adjusted EBITDA Range	**$1,357**	**$1,240**	**$1,340**
Cash Interest	($519)	~($545)	
Changes in Net Working Capital[1]	$95	~($70)	
Changes in Other Assets and Liabilities	($6)	~($20)	
Contingent Consideration	($55)	~($25)	
Cash Taxes, net refund (payments)	($10)	~($10)	
Milestone/Commercial Payments	($45)	~($25)	
Restructuring and Integration Related Costs	($75)	~($20)	
Cash Flow from Operations – Pre-Mesh and Other Settlements	**$743**	**~$525**	**~$625**
Non-Mesh Settlement Payments, net[2]	($74)	~($120)	
Cash Distributions to Settle Mesh Claims[3]	($401)	~($500)	
Cash Flow from Operations	**$267**	**~($95)**	**~$5**
Change in Restricted Cash - Mesh Related	$14	~$40	
Change in Restricted Cash - Non-Mesh Settlements	($17)	~$0	
Capital Expenditures	($87)	~($95)	
Acquisitions and Other[4]	$20	~($25)	
Cash Flow Prior to Debt Payments	**$197**	**~($175)**	**~($75)**

Cash into the mesh QSF and paid mesh legal expenses: FY'18: (~$387M) FY '19: (~$460M)

[1] "Changes in Net Working Capital" defined as changes in Accounts Receivable adjusted for non-cash items, plus changes in Inventory adjusted for long-term and non-cash items, less changes in Accounts Payable adjusted for Royalties and Rebates (additional detail available in earnings release issued February 28, 2019.

[2] "Non-Mesh Settlement Payments" represent legal settlements that Endo paid in 2018 and expects to be paid during 2019.

[3] "Cash Distributions to Settle Mesh Claims " represents expected direct payments and payments from Qualified Settlement Funds to settle mesh product liabilities, as well as mesh related legal expenses.

[4] "Acquisition and Other" includes acquisition cost, contingent consideration for certain products, capital lease payments, cash flows from the sales of businesses and other assets and certain other items.

Table may not total due to rounding

Evolving our Strategic Priorities
Recognizing our progress and defining next phase

1 Reshape our Organization for Success

- **Simplify** our business through process and technology enhancements
- **Drive** productivity improvements
- **Leverage** the new Endo Culture to develop, retain and attract top talent

2 Build Our Portfolio and Capabilities for the Future

- **Expand** the breadth of our Sterile Injectables portfolio
- **Invest** in the continued growth of our highly focused Specialty portfolio
- **Strengthen** our Generics business portfolio and profile for the future
- **Execute** to flawlessly bring the first injectable treatment for cellulite to market

3 Drive Margin Expansion and De-Lever

- **Drive** EBITDA margin improvements through operational execution and continuous improvements
- **De-lever** 3-4x range over time; committed to a highly disciplined capital allocation approach
- **Accelerate** return to EBITDA dollar growth through smart business development

Q&A

Appendix

Cash Conversion Cycle

We use days sales outstanding (DSO), days inventory outstanding (DIO) and days payable outstanding (DPO), the sum of which is the cash conversion cycle, to evaluate our working capital performance. The following table summarizes the details of the financial metrics used to calculate these working capital performance statistics for the quarters ended December 31, 2018, September 30, 2018, June 30, 2018, March 31, 2018 and December 31, 2017 (in thousands except for ratios):

		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017
	Total Revenue	**$786,389**	**$745,466**	**$714,696**	**$700,527**	**$768,645**
DSO	• Accounts Receivable, net of allowance	$470,570	$467,156	$451,240	$460,019	$517,436
	• Less: Returns and allowances	$(236,946)	$(250,637)	$(276,677)	$(293,840)	$(291,034)
	Accounts Receivable, adjusted for non-cash items	$233,624	$216,519	$174,563	$166,179	$226,402
	Total revenues per day	*$8,548*	*$8,103*	*$7,854*	*$7,784*	*$8,355*
	DSO	**27**	**27**	**22**	**21**	**27**
DIO	• Inventories, net	$322,179	$332,787	$343,318	$376,650	$391,437
	• Plus: Long-term inventory	$8,114	$13,306	$11,258	$18,368	$17,146
	• Less: Inventory step-up	$0	$(71)	$(124)	$(66)	$(109)
	Inventory, adjusted for long-term and non-cash items	$330,293	$346,022	$354,452	$394,952	$408,474
	Total revenues per day	*$8,548*	*$8,103*	*$7,854*	*$7,784*	*$8,355*
	DIO	**39**	**43**	**45**	**51**	**49**
DPO	• Trade Accounts Payable	$96,024	$106,321	$95,195	$87,235	$85,348
	• Plus: Accrued Royalties and Partner Payables	$122,028	$103,673	$148,326	$137,868	$63,114
	• Plus: Accrued Rebates and Chargebacks paid in cash	$147,831	$154,319	$52,515	$59,607	$182,937
	Trade Accounts Payable, adjusted for royalties and rebates	$365,883	$364,313	$296,036	$284,710	$331,399
	Total revenues per day	*$8,548*	*$8,103*	*$7,854*	*$7,784*	*$8,355*
	DPO	**43**	**45**	**38**	**37**	**40**
	Cash Conversion Cycle	**23**	**24**	**30**	**36**	**36**

endo

Endo International plc

Q4 2018
Earnings Report

February 28, 2019

endo